Topical clobetasol is effective for the treatment of Toxic epidermal necrolysis (TEN), a rare systemic allergic drug eruption.

  • The efficacy and safety of TC is evaluated in 15 patients with TEN.
  • The patients were advised to apply TC once-daily for 14 days.
  • On day 3 of therapy, a biopsy was taken from the treated area for genetic studies.
  • The primary study established the safety of topical clobetasol treatment and determined the time to cessation of skin detachment for the control and clobetasol-treated areas.
  • Secondary endpoints evaluated the efficacy using parameters such as time to 90% re-epithelialization and percentage of affected skin at 0, 3, 6, 9, 12 and 15 days.
  • Genomic DNA and RNA obtained from biopsy samples characterized the TEN transcriptome and identified the changes in gene expression after topical steroid treatment.
  • Topical steroids have shown promising results in reducing ocular disease duration, severity, and long-term visual sequelae in patients with TEN.
  • This trial will investigate clinical and molecular outcomes of topical clobetasol application and hopefully provide insight into the disease pathophysiology.
  • This trial will serve as a proof-of-concept study to assess safety and efficacy, and may serve as a basis for future large controlled trials of topical steroids.
Citation
Wilken et al., Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial, Trials, 2015.
Reference
Trials Journal

Leave a Reply

Get DrBond

Stop Procrastinating. Start Bonding! Get the App on your phone to bond with the medical world, while on the go!
Apps StorePlay Store
What do you need help with?